Investigating a new medication for treating alcohol use disorder
CB1 Neutral Antagonists for Alcohol Use Disorder
This study is testing a new medication called AM6527 to see if it can help people with Alcohol Use Disorders by providing a safer option than current treatments, and some patients may have the chance to participate in trials to see how well it works.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northeastern University NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10897113 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication, AM6527, which acts as a neutral antagonist of the CB1 receptor to treat Alcohol Use Disorders (AUD). Current treatments have limitations and often come with adverse side effects, making it crucial to find safer alternatives. The study aims to advance AM6527 through preclinical trials, assessing its safety and effectiveness without the negative effects seen in previous medications. Patients may be involved in trials to evaluate how well this new drug works compared to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol use disorder who have not responded well to existing treatments.
Not a fit: Patients who are not diagnosed with alcohol use disorder or those who have contraindications to cannabinoid-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective medication for individuals struggling with alcohol use disorder.
How similar studies have performed: Previous research on cannabinoid receptor antagonists has shown promise, but this specific approach with AM6527 is novel and has not been extensively tested in humans.
Where this research is happening
Boston, United States
- Northeastern University — Boston, United States (Active)
Researchers
- Principal investigator: Makriyannis, Alexandros — Northeastern University
- Study coordinator: Makriyannis, Alexandros
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.